References
- Lacy SE, Barrans SL, Beer PA, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report. Blood. 2020 May 14;135(20):1759–1771.
- Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018 Oct 11;379(15):1416–1430.
- Gerstung M, Papaemmanuil E, Martincorena I, et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet. 2017 Mar;49(3):332–340.
- Nyquist MD, Corella A, Coleman I, et al. Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep. 2020 May 26;31(8):107669.
- Datta J, Smith J, Chatila W, et al. Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2020 Mar 1;26(5):1077–1085.
- Costa C, Wang Y, Ly A, et al. PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer. Cancer Discov. 2020 Jan;10(1):72–85.
- Available from: www.aacr.org/professionals/research/aacr-project-genie/
- Loveday C, Litchfield K, Proszek PZ, et al. Genomic landscape of platinum resistant and sensitive testicular cancers. Nat Commun. 2020 May 4;11(1):2189.
- The ICGC/TCGA pan-cancer analysis of whole genomes consortium. Pan-cancer analysis of whole genomes. Nature. 2020;578(7793):82–93.
- CRUK: What is Cancer? [cited 2020 Sep 29]. Available from: www.cancerresearchuk.org/about-cancer/what-is-cancer
- Global Oncology Trends. 2018: innovation, expansion and disruption. Parsippany (NJ): IQVIA Institute for Human Data Science; 2018 May.
- Foley, Vale, Foley TJ, et al. What role for learning health systems in quality improvement within healthcare providers? Learn Health Sys. 2017 May 31;1(4):e10025.
- Available from: www.gminsights.com/pressrelease/digital-health-market
- Fiore LD & Lavori PW. Integrating randomized comparative effectiveness research with patient care. N Engl J Med. 2016 Jun 2;374(22):2152–2158.
- Weber JS, Levit LA, Adamson PC, et al. Reaffirming and clarifying the American society of clinical oncology’s policy statement on the critical role of phase I trials in cancer research and treatment. J Clin Oncol. 2017 Jan 10;35(2):139–140.
- Moorcraft SY, Marriott C, Peckitt C, et al. Patients’ willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. Trials. 2016 Jan 9;17(1):17.
- Available from: www.nihr.ac.uk/documents/impact-and-value-report/21427